The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent

The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent

Abstract The Toll-like receptor 8 (TLR8) agonist VTX-2337 (motolimod) is an anti-cancer immunotherapeutic agent that is believed to augment natural killer (NK) and dendritic cell (DC) activity. The goal of this work is to examine the role of TLR8 expression/activity in head and neck squamous cell ca...

Full description

Bibliographic Details
Main Authors: Yinwen Cheng, Nicholas Borcherding, Ayomide Ogunsakin, Caitlin D. Lemke-Miltner, Katherine N. Gibson-Corley, Anand Rajan, Allen B. Choi, Wattawan Wongpattaraworakul, Carlos H. F. Chan, Aliasger K. Salem, George J. Weiner, Andrean L. Simons
Format: Article
Language:English
Published: Nature Publishing Group 2021-01-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-020-80957-z

Internet

https://doi.org/10.1038/s41598-020-80957-z

Similar Items